Affinity Asset Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Affinity Asset Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$1.05M	–	88
2024 Q3	$1.05M	Buy	+15,000	New	+$1.25M	0.14%	73
2023 Q2	–	Sell	-25,000	Closed	-$2.43M	–	74
2023 Q1	$2.43M	Sell	25,000 -55,000	-69%	-$5.7M	0.8%	35
2022 Q4	$8.28M	Buy	+80,000	New	+$7.51M	3.25%	6

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Affinity Asset Advisors's BMRN Position: Q4 2024 in Review

Affinity Asset Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 15,000 shares — an estimated $1.05M sold.

Affinity Asset Advisors first reported a position in BMRN in Q4 2022 and held it in 3 quarters. The position peaked at $8.28M in Q4 2022. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Affinity Asset Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Affinity Asset Advisors sold 15,000 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.05M.
Affinity Asset Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Affinity Asset Advisors's BioMarin Pharmaceuticals position peaked at $8.28M in Q4 2022.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.